Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Journal of Comparative Effectiveness Research|January 23, 2016
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparisonElyse Swallow, Caroline Kelley, James Signorovitch, et al.Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Antiepileptic Drug Titration and Related Health Care Resource Use and CostsJesse Fishman, Linda Kalilani, Yan Song, et al.CNS Drugs|September 1, 2017
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?Elyse Swallow, Anna Fang, James Signorovitch, et al.Plos One|October 14, 2016
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular DystrophyNathalie Goemans, Marleen Vanden Hauwe, James Signorovitch, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 7, 2023
Burden of Illness and Treatment Patterns Among Patients With von Willebrand Disease in US Clinical PracticeElyse Swallow, Jessica R Marden, Emma Billmyer, et al.Advances in Therapy|May 8, 2025
Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United StatesNana Kragh, Andrew Worsfold, Abiola Oladapo, et al.Neuromuscular Disorders : NMD|July 18, 2016
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophyEugenio Mercuri, James Edward Signorovitch, Elyse Swallow, et al.Journal of Comparative Effectiveness Research|June 4, 2020
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysisElyse Swallow, Oscar Patterson-Lomba, Rajeev Ayyagari, et al.Current Medical Research and Opinion|March 28, 2014
Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012Elyse Swallow, Jie Zhang, Darren Thomason, et al.Journal of Managed Care & Specialty Pharmacy|March 27, 2018
The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell CarcinomaElyse Swallow, Andrew Messali, Sameer Ghate, et al.Pageof 7